Share This Page
Drug Price Trends for NDC 00121-4721
✉ Email this page to a colleague
Average Pharmacy Cost for 00121-4721
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| No data available in table | ||||
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00121-4721
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| FLUOXETINE HCL 20MG/5ML SOLN,ORAL,5ML | Golden State Medical Supply, Inc. | 00121-4721-05 | 40X5ML | 178.97 | 2023-06-23 - 2028-06-14 | FSS | |
| FLUOXETINE HCL 20MG/5ML SOLN,ORAL,5ML | Golden State Medical Supply, Inc. | 00121-4721-05 | 40X5ML | 167.60 | 2023-06-15 - 2028-06-14 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00121-4721
The pharmaceutical industry is a complex and ever-evolving sector, with drug pricing and market dynamics playing crucial roles in shaping its landscape. In this comprehensive analysis, we'll delve into the market trends and price projections for the drug identified by the National Drug Code (NDC) 00121-4721. While specific information about this particular NDC is limited in the provided search results, we can draw insights from broader industry trends and similar drug pricing patterns to provide a thorough market analysis.
Understanding the Pharmaceutical Market Landscape
The pharmaceutical market is experiencing significant growth, particularly in the biopharma and biotech sectors. The biopharma market is projected to grow at a compound annual growth rate (CAGR) of 7.56% between 2024 and 2029, while the biotech sector is expected to grow at a CAGR of 9.4% between 2021 and 2027[3]. This growth is driven by various factors, including technological advancements, evolving regulatory frameworks, and a shift towards patient-centered care.
The Role of Generic Drugs
Generic drugs play a vital role in the pharmaceutical market, often providing more stable pricing due to increased competition. While we don't have specific information about whether NDC 00121-4721 is a generic or brand-name drug, understanding the dynamics of generic drug pricing can provide valuable insights.
Historically, generic drugs have seen significant price volatility. For instance, a generic version of naproxen experienced a 2,527% price increase between 2012 and 2021[1].
This example highlights the potential for dramatic price changes in the generic drug market, although such extreme cases are not common.
Price Transparency and Regulatory Oversight
Price transparency has become a critical issue in the pharmaceutical market. Regulatory bodies have implemented drug price transparency programs to monitor and report price increases and new high-cost drugs. These programs require manufacturers to report price changes and provide detailed information on the reasons behind these changes[1].
Impact of Regulatory Changes
Regulatory changes can significantly influence drug pricing. For example, some states have proposed implementing upper payment limits for certain drugs, which could cap the maximum price that can be charged[1]. Such changes could potentially affect the pricing strategy for NDC 00121-4721, depending on its classification and market position.
Market Competition and Generic Drug Pricing
The presence of multiple generic manufacturers ensures a competitive market, which generally keeps prices in check. As patents expire for brand-name drugs, the entry of generic versions can lead to a decrease in overall market prices.
Example: Imatinib Mesylate
While not directly related to NDC 00121-4721, the pricing trends for Imatinib Mesylate (NDC 00378-2245) can provide some insight. The price per unit of Imatinib Mesylate has shown a declining trend over recent months, from $0.66780 per unit in December 2024 to $0.54917 per unit in October 2024[5]. This decline could be attributed to increased competition or improved manufacturing efficiencies.
Projected Drug Price Increases
According to Vizient, Inc., drug price inflation is projected to grow at 3.8% in the latest Pharmacy Market Outlook. This increase is driven in part by specialty pharmacy, including the increasing utilization of weight loss drugs[2].
Specialty Pharmaceuticals
Specialty pharmaceuticals, which treat high-cost, complex, or chronic conditions such as cancer, infectious, autoimmune, and pulmonary conditions, make up the majority of the top 15 medications in spend among Vizient pharmacy program participants. The projected price increase for specialty medications is 4.18%[2].
U.S. Drug Pricing Compared to Global Markets
It's important to consider the global context when analyzing drug pricing. In 2022, the average price per unit in the U.S. was 5.5 times as high as in the OECD (excluding U.S.) and 7.7 times as high as the rest of the world (excluding U.S.)[4]. This disparity represents both higher prices and a drug mix that skews towards higher-cost drugs in the U.S. market.
Retail vs. Non-Retail Markets
Breaking down the market into retail (e.g., pharmacies) and non-retail (e.g., hospitals and physician offices) segments reveals interesting trends:
- U.S. sales revenues grew similarly in both retail (22%) and non-retail (26%) markets.
- In contrast, both the rest of the world and OECD (excluding U.S.) shrunk in the retail market (-6% and -4% respectively) but grew in the non-retail market (13% and 12%)[4].
Technological Advancements and Drug Development
The pharmaceutical industry is witnessing significant technological advancements that are reshaping drug development and pricing strategies. Artificial Intelligence (AI) and machine learning are playing increasingly important roles in accelerating research and development processes.
AI in Drug Development
Many pharmaceutical companies are investing heavily in AI to foster innovation and reduce drug development costs and timelines. For example:
- Amgen has doubled its clinical trial enrollment speed using a multimodal, data-driven machine learning tool.
- BMS is using AI and machine learning to advance protein degradation science.
- Sanofi is collaborating with OpenAI and Formation Bio to develop an AI tool that reduces patient recruitment timelines "from months to minutes"[7].
These advancements could potentially lead to more efficient drug development processes, which might influence pricing strategies for drugs like NDC 00121-4721.
Supply Chain Optimization and Resilience
The pharmaceutical industry is increasingly focusing on optimizing supply chains and building resilience using technology, especially AI. More than 85% of biopharma executives surveyed say they are investing in data, AI, and digital tools in 2025 to build supply chain resiliency[7].
Smart Manufacturing
90% of biopharma executives said they are investing in smart manufacturing to increase supply chain efficiency. Companies like Amgen and Roche are leading examples of this trend[7]. These investments in supply chain optimization could potentially lead to cost savings, which might influence drug pricing strategies.
Evolving Portfolio Strategies
Pharmaceutical companies are increasingly adopting new modalities and mechanisms of action (MOAs) as they focus on diverse and robust portfolios to redefine standards of care. Emerging modalities driving this surge include:
- Fusion proteins
- Oligonucleotide therapies
- Multispecific antibodies
- Antibody drug conjugates
- Radioligand therapies
- Oncolytic viruses[7]
These evolving portfolio strategies could potentially impact the market position and pricing of existing drugs, including NDC 00121-4721.
Focus on High Unmet Needs
Drugmakers are increasingly shifting focus to therapy areas (TAs) that are broadly perceived to have high unmet needs. About half of the 10 largest pharma companies are focusing on TAs beyond core areas such as oncology and immunology[7]. This shift in focus could potentially influence market dynamics and pricing strategies across various drug categories.
The "Always Be Launching" Mindset
To sustain revenue in a challenging environment, many pharmaceutical companies are adopting an "always be launching" mindset. For example, GSK expects to launch 12 new treatments in 2025[7]. This approach of continuous product launches could potentially impact market competition and pricing strategies for existing drugs.
Patient-Centric Clinical Trials
Pharmaceutical companies are continuing to focus on making clinical trials more inclusive and patient-centric. This trend towards patient-centricity could potentially influence drug development costs and, by extension, pricing strategies.
Key Takeaways
- The pharmaceutical market is experiencing significant growth, particularly in the biopharma and biotech sectors.
- Generic drugs play a crucial role in market dynamics, often providing more stable pricing due to increased competition.
- Regulatory changes and price transparency initiatives are significantly influencing drug pricing strategies.
- The U.S. drug prices are substantially higher compared to global markets, with an average price per unit 5.5 times higher than in OECD countries (excluding U.S.).
- Technological advancements, particularly in AI and machine learning, are reshaping drug development processes and potentially influencing pricing strategies.
- Supply chain optimization and resilience are becoming increasingly important factors in the pharmaceutical industry.
- Evolving portfolio strategies and a focus on high unmet needs are shaping the future of drug development and market dynamics.
- The "always be launching" mindset and patient-centric clinical trials are emerging trends that could impact market competition and pricing strategies.
FAQs
-
Q: What factors influence drug pricing in the pharmaceutical market? A: Drug pricing is influenced by various factors, including research and development costs, manufacturing expenses, market competition, regulatory requirements, and the drug's perceived value in treating specific conditions.
-
Q: How do generic drugs impact the pharmaceutical market? A: Generic drugs often lead to more stable pricing due to increased competition. They typically enter the market after patent expiration of brand-name drugs, leading to overall market price decreases.
-
Q: What role does AI play in modern drug development? A: AI is increasingly used to accelerate research and development processes, optimize clinical trial recruitment, and advance scientific understanding in areas like protein degradation.
-
Q: How does the U.S. pharmaceutical market differ from global markets? A: The U.S. market generally has higher drug prices compared to other countries. In 2022, the average price per unit in the U.S. was 5.5 times higher than in OECD countries (excluding U.S.).
-
Q: What is the "always be launching" mindset in the pharmaceutical industry? A: This approach involves continuously developing and launching new treatments to sustain revenue and reduce reliance on blockbuster drugs. For example, GSK plans to launch 12 new treatments in 2025.
Sources cited: [1] https://www.drugpatentwatch.com/p/drug-price/ndc/00378-0167 [2] https://www.vizientinc.com/newsroom/news-releases/2024/vizient-projects-3-8-drug-price-increase-driven-by-specialty-pharmaceuticals [3] https://www.pwc.com/us/en/industries/pharma-life-sciences/pharmaceutical-industry-trends.html [4] https://aspe.hhs.gov/sites/default/files/documents/4326cc7fe43bc11770598cf2a13f478c/international-market-size-prices.pdf [5] https://www.wolterskluwer.com/en/expert-insights/are-you-prepared-for-a-major-industry-change-to-the-national-drug-code-ndc-number [7] https://www.zs.com/insights/pharmaceutical-trends-2025-outlook-ai-supplychain-and-beyond
More… ↓
